What is the current research progress on the role of the JAK/STAT/mTOR pathway in liver inflammation during liver failure, and is it considered a core pathway in this process?

Liver cancer remains one of the most prevalent malignancies worldwide with high incidence and mortality rates. Due to its subtle onset, liver cancer is commonly diagnosed at a late stage when surgical interventions are no longer feasible. This situation highlights the critical role of systemic treatments, including targeted therapies, in bettering patient outcomes. Despite numerous studies on the mechanisms underlying liver cancer, tyrosine kinase inhibitors (TKIs) are the only widely used clinical inhibitors, represented by sorafenib, whose clinical application is greatly limited by the phenomenon of drug resistance.
Current research positions the JAK/STAT/mTOR pathway as a core, central mechanism driving liver inflammation and injury during liver failure. The pathway serves as a vital signal integration hub that translates pro-inflammatory cytokine surges (such as IL-6) into uncontrolled hepatic inflammation, hepatocyte apoptosis, and inhibition of regeneration. 
Looking the more recent research studies we may point out a list of more relevant observations:

1)       Recent studies confirm that IL-6-activated JAK/STAT3 is crucial in early liver repair, but persistent activation promotes severe inflammation and hepatocyte injury. mTORC1 downstream of this pathway regulates hepatic metabolism and energy during injury. 

2)      Research highlights a complex network where NF-κB and JAK/STAT3 pathways act synergistically to increase pro-inflammatory cytokine production, creating a vicious cycle.

3)      Inhibition of JAK proteins (e.g., ruxolitinib, baricitinib) or downstream STAT3 in preclinical models effectively reduces hepatocellular carcinoma (HCC) progression, which often stems from chronic inflammation and liver failure.

4)      Studies emphasize that STAT1 activation drives apoptosis (harmful) while STAT3 is generally protective against acute liver injury. However, in chronic contexts, STAT3 often drives the inflammation and angiogenesis that lead to further failure